advertisement
Advances in Therapy 18
Showing records 1 to 18 | Display all abstracts in Advances in Therapy98725 iStent inject Trabecular Micro-Bypass with or Without Cataract Surgery Yields Sustained 5-Year Glaucoma Control
Hengerer FH
Advances in Therapy 2022; 39: 1417-1431
99106 Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
Miki A
Advances in Therapy 2022; 39: 2085-2095
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Nakazawa T
Advances in Therapy 2022; 39: 1359-1374
98804 Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
Tanihara H
Advances in Therapy 2022; 39: 1659-1677
99106 Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
Miyamoto E
Advances in Therapy 2022; 39: 2085-2095
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Takahashi K
Advances in Therapy 2022; 39: 1359-1374
98725 iStent inject Trabecular Micro-Bypass with or Without Cataract Surgery Yields Sustained 5-Year Glaucoma Control
Auffarth GU
Advances in Therapy 2022; 39: 1417-1431
98804 Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
Kakuda T
Advances in Therapy 2022; 39: 1659-1677
99106 Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
Ishida N
Advances in Therapy 2022; 39: 2085-2095
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Kuwayama Y
Advances in Therapy 2022; 39: 1359-1374
98804 Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
Sano T
Advances in Therapy 2022; 39: 1659-1677
98725 iStent inject Trabecular Micro-Bypass with or Without Cataract Surgery Yields Sustained 5-Year Glaucoma Control
Conrad-Hengerer I
Advances in Therapy 2022; 39: 1417-1431
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Nomura A
Advances in Therapy 2022; 39: 1359-1374
98804 Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
Kanno T
Advances in Therapy 2022; 39: 1659-1677
99106 Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
Shii D; Hori K
Advances in Therapy 2022; 39: 2085-2095
98619 Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
Shimada F
Advances in Therapy 2022; 39: 1359-1374
98804 Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
Kurihara Y
Advances in Therapy 2022; 39: 1659-1677
99106 Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
Advances in Therapy 2022; 39: 2085-2095